Others proposed the activity of the alternative nonhomologous end-joining (alt-NHEJ) pathway in resistant CML cells driven by BCR-ABL1 and/or MYC transcriptional activity (10, 11). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.